SCHEDULE: Paradigm BioCapital Discloses 5.1% Stake in Viridian
Schedule 13G
Paradigm BioCapital Advisors LP and affiliates have reported a 5.1% beneficial ownership stake in Viridian Therapeutics, Inc.
Summary
- Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. filed a Schedule 13G.
- The reporting persons collectively beneficially own 5,633,788 shares of Viridian Therapeutics, Inc. common stock.
- This ownership represents 5.1% of the issuer's outstanding common stock.
- The filing confirms the shares were acquired for investment purposes without the intent to change or influence control of the company.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral regulatory disclosure reflecting standard institutional portfolio activity.
Positives
- Institutional investment interest from Paradigm BioCapital indicates confidence in the company's long-term prospects.
Negatives
- None noted.
Risks
- Market volatility associated with biotechnology sector investments.
- Regulatory and clinical trial risks inherent to the issuer's business model.
Future Outlook
The reporting persons state the securities were not acquired for the purpose of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that the accumulation of a 5% stake by specialized biotech investment firms like Paradigm BioCapital is a common indicator of institutional support for mid-cap clinical-stage pharmaceutical companies.
Comparison to Industry Standards
- The filing follows standard regulatory requirements for institutional investors crossing the 5% ownership threshold.
- The passive investment stance is consistent with typical Schedule 13G filings for investment funds.
Stakeholder Impact
- Shareholders may view the entry of a new 5% institutional holder as a sign of market validation.
Next Steps
- Reporting persons may file amendments if there are material changes in their percentage of ownership.
Key Dates
| Date | Description |
|---|---|
| 2026-05-08 | Issuer filed Prospectus Supplement. |
| 2026-05-11 | Issuer filed Form 8-K; date used for outstanding share count. |
| 2026-06-18 | Date of event requiring the filing of the Schedule 13G. |
| 2026-06-26 | Date of the filing and execution of the Joint Filing Agreement. |
Keywords
Viridian Therapeutics, Schedule 13G, Paradigm BioCapital, Institutional Ownership, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.